多西他赛联合卡培他滨对胃癌根治术后患者的临床疗效分析  

Clinical Efficacy of Docetaxel and Capecitabine in the Treatment of Gastric Cancer after Radical Surgery

作　　者：吴祖蛟 吴火友[1] 穆建成[1] WU Zujiao;WU Huoyou;MU Jiancheng(Department of Gastroenterology,The First Hospital of Nanping,Fujian Medical University,Nanping 353000,Fujian Province,China)

机构地区：[1]福建医科大学附属南平市第一医院胃肠二科,福建南平353000

出　　处：《中国实用乡村医生杂志》2024年第3期16-19,共4页Chinese Practical Journal of Rural Doctor

摘　　要：目的探讨多西他赛联合卡培他滨对胃癌根治术后患者的临床疗效。方法选择2021年1月—2022年6月福建医科大学附属南平市第一医院收治的60例胃癌患者作为研究对象,所有患者均于我院肿瘤科就诊并行胃癌根治术。将60例患者随机分为观察组和对照组各30例,两组患者采用不同的术后化疗方案。对照组于术后2~4周采用多西他赛联合奥沙利铂、5-氟尿嘧啶化疗方案,观察组于术后2~4周采用多西他赛联合卡培他滨化疗方案。比较两组化疗后的肿瘤控制率、肿瘤退缩情况及化疗毒性反应。结果疗程结束后观察组肿瘤控制率96.67%高于对照组的70.00%,观察组化疗敏感率93.33%高于对照组的73.33%,差异均有统计学意义(P<0.05);观察组和对照组化疗后手足综合征、恶心呕吐、外周神经毒性发生率比较,差异无统计学意义(P>0.05);观察组骨髓抑制率低于对照组,差异有统计学意义(P<0.05)。结论多西他赛联合卡培他滨对胃癌患者行根治术后的肿瘤控制疗效较好,化疗敏感性较高,有助于减轻骨髓抑制化疗毒副反应。Objective To investigate the clinical efficacy of docetaxel and capecitabine on gastric cancer after radical surgery.Methods A total of 60 patients with gastric cancer were selected from January 2021 to June 2022 as the subjects in The First Hospital of Nanping,Fujian Medical University,and all the patients were treated in the Department of Oncology of our hospital and underwent radical gastric cancer surgery.The 60 study patients were divided into the observation group and the control group based on different postoperative chemotherapy regimens.The control group was treated with docetaxel combined with oxaliplatin and 5-fluorouracil chemotherapy regimen at 2~4 weeks after surgery,while the observation group was treated with docetaxel combined with capecitabine chemotherapy regimen at 2~4 weeks after surgery.Tumour control rate,tumour regression and chemotherapy toxicity reaction were compared between the two groups after chemotherapy.Results The tumour control rate of the observation group was 96.67%,which was significantly higher than that of the control group of 70.00% at the end of the course of treatment(P<0.05).The chemotherapy-sensitive rate of the observation group was 93.33%,which was significantly higher than that of the control group of 73.33% at the end of the course of treatment(P<0.05).There was no significant difference in the incidence of hand-foot syndrome,nausea and vomiting,and peripheral neurotoxicity between two groups after chemotherapy(P>0.05).The rate of myelosuppression in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Docetaxel and capecitabine have better efficacy in tumour control after radical surgery for gastric cancer patients,and have higher sensitivity to chemotherapy,which helps to reduce the toxic side effects of myelosuppressive chemotherapy.

关 键 词：多西他赛 卡培他滨 胃癌根治术 化疗毒副反应 

分 类 号：R735.2[医药卫生—肿瘤]